MGEN 30 min Chart and Analysis
Monday July 27th, 2020
9:14am Eastern Time
----------------- Disclaimer Read This first please. It's important.--------------------
Please don't take this as a financial advice, remember I'm not a professional analytic, this whole idea is based on my knowledge,
interpretation and opinion. This is only my Idea, don't buy or sell because of my idea. Do your own research in the company before
deciding either buy or sell. Remember there is always a risk of losing money when you trade or invest in any stock, you must decide at your own risk.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Indicators in the Chart
• SMA 200
• SMA 60
• SMA 50
• Pivot Reversal Strategy
• RSI
• MACD
• Bollinger Bands
• EMA 15
• Fibonacci Retracement
• Parabolic Sar
Chart patterns
• Stairs Pattern from July 14th, 2020
• High lows
• High Highs
Interpretation of the indicators
• RSI at 49 without being oversold for the moment.
• MACD is getting Bullish and Curling Up
• Bollinger Band are getting Bullish and the candles are trading above the middle line.
• Candles trading above EMA 15, above SMA 200 and Below SMA 50.
• Parabolic Sar is below the candles (Bullish Signs).
• Pivot Reversal Strategy is marking a bottom reversal.
• Fibonacci is showing a range of possible Price Targets. Fib Retracement overall range $1.36 to $3.41. All these price targets are from the Fibonacci Retracement.
Recently News
• Cobomarsen Receives Orphan Drug Designation from the U.S. FDA for the Treatment of T-cell Lymphoma. July 23rd,2020.
• miRagen Regains Compliance with Nasdaq Listing Requirements. July 2nd, 2020.
• Announced preclinical safety and efficacy data for MRG-229, which is being evaluated for idiopathic pulmonary fibrosis. It demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems. June 23rd, 2020.
Analyst Price Forecast
• Money CNN, the 5 analysts offering 12-month price forecasts for miRagen Therapeutics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +306.50% increase from the last price of 1.23.
• Market Beat, Miragen Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside According to analysts' consensus price target of $5.00, Miragen Therapeutics has a potential upside of 303.2% from its current price of $1.24. Amount of Analyst Coverage Miragen Therapeutics has only been the subject of 3 research reports in the past 90 days.
• Tip Ranks based on 4 analysts offering 12-month price targets for Miragen Therapeutics in the last 3 months. The average price target is $5.50 with a high forecast of $6.00 and a low forecast of $5.00. The average price target represents a 343.55% increase from the last price of $1.24.
Summary
The stock with ticker MGEN in our opinion it has a decent pipeline and opportunity of a high growth in the market. Their Pipeline have two developments in Phase 2, three mores in phase 1 and o2 more in preclinical. Analytics are giving a good price target for a future and they are getting positive news recently. Fundamental data is not bad but is getting better with a good progress. Indicators in the 30-minute chart looks good also the 4 hours and daily chart.
References
finance.yahoo.com/news/cobomarsen-receives-orphan-drug-designation-203200790.html
finance.yahoo.com/news/miragen-regains-compliance-nasdaq-listing-201510311.html
finance.yahoo.com/news/daily-biotech-pulse-sanofi-expedites-115759692.html
finviz.com/quote.ashx?t=MGEN
investors.miragen.com/press-releases/press-release/2020/Cobomarsen-Receives-Orphan-Drug-Designation-From-the-U.S.-FDA-for-the-Treatment-of-T-cell-Lymphoma/default.aspx
investors.miragen.com/press-releases/press-release/2020/miRagen-Regains-Compliance-With-Nasdaq-Listing-Requirements/default.aspx
investors.miragen.com/press-releases/press-release/2020/miRagen-Announces-Encouraging-Preclinical-Safety-and-Efficacy-Data-for-its-Next-generation-miR-29-Replacement-Product-Candidate-Intended-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis/default.aspx
d18rn0p25nwr6d.cloudfront.net/CIK-0001590750/d99f5111-0875-4b5a-9321-d3684d2dd9ca.html
d18rn0p25nwr6d.cloudfront.net/CIK-0001590750/e3abefe2-d50c-47ca-a931-286b62150045.html
money.cnn.com/quote/forecast/forecast.html?symb=MGEN
marketbeat.com/stocks/NASDAQ/MGEN/
tipranks.com/stocks/mgen/price-target
9:14am Eastern Time
----------------- Disclaimer Read This first please. It's important.--------------------
Please don't take this as a financial advice, remember I'm not a professional analytic, this whole idea is based on my knowledge,
interpretation and opinion. This is only my Idea, don't buy or sell because of my idea. Do your own research in the company before
deciding either buy or sell. Remember there is always a risk of losing money when you trade or invest in any stock, you must decide at your own risk.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Indicators in the Chart
• SMA 200
• SMA 60
• SMA 50
• Pivot Reversal Strategy
• RSI
• MACD
• Bollinger Bands
• EMA 15
• Fibonacci Retracement
• Parabolic Sar
Chart patterns
• Stairs Pattern from July 14th, 2020
• High lows
• High Highs
Interpretation of the indicators
• RSI at 49 without being oversold for the moment.
• MACD is getting Bullish and Curling Up
• Bollinger Band are getting Bullish and the candles are trading above the middle line.
• Candles trading above EMA 15, above SMA 200 and Below SMA 50.
• Parabolic Sar is below the candles (Bullish Signs).
• Pivot Reversal Strategy is marking a bottom reversal.
• Fibonacci is showing a range of possible Price Targets. Fib Retracement overall range $1.36 to $3.41. All these price targets are from the Fibonacci Retracement.
Recently News
• Cobomarsen Receives Orphan Drug Designation from the U.S. FDA for the Treatment of T-cell Lymphoma. July 23rd,2020.
• miRagen Regains Compliance with Nasdaq Listing Requirements. July 2nd, 2020.
• Announced preclinical safety and efficacy data for MRG-229, which is being evaluated for idiopathic pulmonary fibrosis. It demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems. June 23rd, 2020.
Analyst Price Forecast
• Money CNN, the 5 analysts offering 12-month price forecasts for miRagen Therapeutics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +306.50% increase from the last price of 1.23.
• Market Beat, Miragen Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside According to analysts' consensus price target of $5.00, Miragen Therapeutics has a potential upside of 303.2% from its current price of $1.24. Amount of Analyst Coverage Miragen Therapeutics has only been the subject of 3 research reports in the past 90 days.
• Tip Ranks based on 4 analysts offering 12-month price targets for Miragen Therapeutics in the last 3 months. The average price target is $5.50 with a high forecast of $6.00 and a low forecast of $5.00. The average price target represents a 343.55% increase from the last price of $1.24.
Summary
The stock with ticker MGEN in our opinion it has a decent pipeline and opportunity of a high growth in the market. Their Pipeline have two developments in Phase 2, three mores in phase 1 and o2 more in preclinical. Analytics are giving a good price target for a future and they are getting positive news recently. Fundamental data is not bad but is getting better with a good progress. Indicators in the 30-minute chart looks good also the 4 hours and daily chart.
References
finance.yahoo.com/news/cobomarsen-receives-orphan-drug-designation-203200790.html
finance.yahoo.com/news/miragen-regains-compliance-nasdaq-listing-201510311.html
finance.yahoo.com/news/daily-biotech-pulse-sanofi-expedites-115759692.html
finviz.com/quote.ashx?t=MGEN
investors.miragen.com/press-releases/press-release/2020/Cobomarsen-Receives-Orphan-Drug-Designation-From-the-U.S.-FDA-for-the-Treatment-of-T-cell-Lymphoma/default.aspx
investors.miragen.com/press-releases/press-release/2020/miRagen-Regains-Compliance-With-Nasdaq-Listing-Requirements/default.aspx
investors.miragen.com/press-releases/press-release/2020/miRagen-Announces-Encouraging-Preclinical-Safety-and-Efficacy-Data-for-its-Next-generation-miR-29-Replacement-Product-Candidate-Intended-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis/default.aspx
d18rn0p25nwr6d.cloudfront.net/CIK-0001590750/d99f5111-0875-4b5a-9321-d3684d2dd9ca.html
d18rn0p25nwr6d.cloudfront.net/CIK-0001590750/e3abefe2-d50c-47ca-a931-286b62150045.html
money.cnn.com/quote/forecast/forecast.html?symb=MGEN
marketbeat.com/stocks/NASDAQ/MGEN/
tipranks.com/stocks/mgen/price-target
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.